Effect of Fluocinolone Acetonide 0.2µg/day (ILUVIEN®) Implant on the Decision to Drive in Patients With Differential Control of DME

Related

• 

  Complications or Are They: Why We Can NEVER Get Enough ReST

  Jeffrey S. Heier, MD

  Peter K. Kaiser, MD FASRS

  Geoffrey G. Emerson, MD, PhD, FASRS

  J. Michael Jumper, MD, FASRS

  Ehab N. ELRAYES, MD, PhD ,FASRS

  Daniel Simhaee, MD

  ASSAF DOTAN, MD

  Paul Hahn, MD, PhD, FASRS

  Philip J. Ferrone, MD, FASRS

  Annual Meeting Talks

  2018

• 

  A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2018

• 

  Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials

  David S. Boyer, MD

  Updates from the Field

  2022